Literature DB >> 3875918

Quantitation of T lymphocytes in human bone marrow by a limiting dilution assay.

N A Kernan, N Flomenberg, N H Collins, R J O'Reilly, B Dupont.   

Abstract

A limiting-dilution microculture assay (LDMA) for quantitation of T lymphocytes in human bone marrow is described. Phytohemagglutinin (PHA)-responsive T cells are maintained in interleukin 2 (IL-2)-containing medium with feeder cells in a total volume of 20 microliter. After 16 days of culture, each well is scored by microscopic examination as positive or negative based on the presence or absence of cell growth. A limiting dilution analysis of the relationship between the number of cells seeded per well and the fraction of wells without growth demonstrate that the data are consistent with single-hit kinetics. Minimum chi square statistics were used to establish the line of best fit to calculate the T lymphocyte frequency in a sample. This method for enumeration of T cells was applied to untreated samples of bone marrow, soybean-agglutinin-negative (SBA-) marrow, and soybean-agglutinin-negative marrow cells subjected to a single sheep red blood cell (SRBC) rosette (SBA-E-) or double SRBC rosette (SBA-E-E-) depletion. It was demonstrated that the LDMA can detect as few as 4.3 X 10(5) T cells in a total of 10(9) bone marrow mononuclear cells. The assay system also allows for a comparison of T lymphocytes in the untreated marrow with the T-cell-depleted marrow samples. The mean number of T cells in untreated marrow was 1 X 10(9) and in T-cell-depleted samples 4.3 X 10(5). This corresponds to a 3.5 log or 99.96% reduction in total T cell number by the SBA-E-rosette technique. The phenotypic analysis of single positive wells as well as pooled cells from all positive wells indicate that at least 95% of the wells scored microscopically as positive for T cell growth did in fact contain T cells. The assay requires only 1 X 10(6) mononuclear cells for complete analysis and, therefore, compares favorably with previously published methods.

Entities:  

Mesh:

Year:  1985        PMID: 3875918     DOI: 10.1097/00007890-198509000-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Authors:  Esperanza B Papadopoulos; Miguel-Angel Perales; Jenna D Goldberg; Joanne F Chou; Steven Horwitz; Julie Teruya-Feldstein; Juliet N Barker; Farid Boulad; Hugo Castro-Malaspina; Sergio Giralt; Ann A Jakubowski; Guenther Koehne; Marcel R M van den Brink; James W Young; Zhigang Zhang
Journal:  Leuk Lymphoma       Date:  2012-01-31

2.  A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation.

Authors:  Xiaodong Tong; Ying Xiong; Maciej Zborowski; Sherif S Farag; Jeffrey J Chalmers
Journal:  Exp Hematol       Date:  2007-08-13       Impact factor: 3.084

3.  CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Authors:  Pere Barba; Rodrigo Martino; Qin Zhou; Christina Cho; Hugo Castro-Malaspina; Sean Devlin; Albert Esquirol; Sergio Giralt; Ann A Jakubowski; Dolores Caballero; Molly Maloy; Esperanza B Papadopoulos; José Luís Piñana; María Laura Fox; Francisco J Márquez-Malaver; David Valcárcel; Carlos Solano; Lucía López-Corral; Jorge Sierra; Miguel-Angel Perales
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-02       Impact factor: 5.742

4.  Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Authors:  Jenna D Goldberg; Junting Zheng; Ravin Ratan; Trudy N Small; Kuan-Chi Lai; Farid Boulad; Hugo Castro-Malaspina; Sergio A Giralt; Ann A Jakubowski; Nancy A Kernan; Richard J O'Reilly; Esperanza B Papadopoulos; James W Young; Marcel R M van den Brink; Glenn Heller; Miguel-Angel Perales
Journal:  Leuk Lymphoma       Date:  2017-01-10

5.  Functional and phenotypical studies of the Leu-4 (CD3)+, Leu-1 (CD5)- T lymphocyte.

Authors:  E F Srour; E B Walker; D E Walker; J Jansen
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

6.  Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

Authors:  Pere Barba; Ravin Ratan; Christina Cho; Izaskun Ceberio; Patrick Hilden; Sean M Devlin; Molly A Maloy; Juliet N Barker; Hugo Castro-Malaspina; Ann A Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Doris M Ponce; Craig Sauter; Roni Tamari; Marcel R M van den Brink; James W Young; Richard J O'Reilly; Sergio A Giralt; Miguel-Angel Perales
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-24       Impact factor: 5.742

7.  T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.

Authors:  Jenna D Goldberg; Alex Linker; Deborah Kuk; Ravin Ratan; Joseph Jurcic; Juliet N Barker; Hugo Castro-Malaspina; Sergio Giralt; Katharine Hsu; Ann A Jakubowski; Robert Jenq; Guenther Koehne; Esperanza B Papadopoulos; Marcel R M van den Brink; James W Young; Farid Boulad; Nancy A Kernan; Richard J O'Reilly; Susan E Prockop; Joachim Yahalom; Glenn Heller; Miguel-Angel Perales
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-13       Impact factor: 5.742

8.  Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.

Authors:  M-A Perales; R Jenq; J D Goldberg; A S Wilton; S S E Lee; H R Castro-Malaspina; K Hsu; E B Papadopoulos; M R M van den Brink; F Boulad; N A Kernan; T N Small; S Wolden; N H Collins; M Chiu; G Heller; R J O'Reilly; T Kewalramani; J W Young; A A Jakubowski
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

9.  Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donors.

Authors:  Alberto Mussetti; Nancy A Kernan; Susan E Prockop; Andromachi Scaradavou; Rachel Lehrman; Julianne M Ruggiero; Kevin Curran; Rachel Kobos; Richard O'Reilly; Farid Boulad
Journal:  Pediatr Hematol Oncol       Date:  2016-10-07       Impact factor: 1.969

10.  Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

Authors:  Juan Montoro; Izaskun Ceberio; Patrick Hilden; Molly A Maloy; Juliet Barker; Hugo Castro-Malaspina; Parastoo Dahi; Guenther Koehne; Miguel-Angel Perales; Doris Ponce; Craig Sauter; Brian Shaffer; Roni Tamari; James W Young; Sergio A Giralt; Richard J O'Reilly; Ann A Jakubowski; Esperanza B Papadopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2019-10-13       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.